Intensity Therapeutics, INC

Intensity Therapeutics, Inc. announced the results of its annual meeting, with stockholders voting to elect directors, ratify the independent auditor, and approve amendments to stock incentive and purchase plans.

Intensity Therapeutics reported Q1 2026 financial results, highlighting positive preliminary data from the INVINCIBLE-4 study in triple-negative breast cancer and plans to resume enrollment in the INVINCIBLE-3 study.

Intensity Therapeutics announced its 2025 year-end financial results, highlighting clinical advancements for INT230-6 and an extended cash runway into Q2 2027.

Intensity Therapeutics, Inc. has increased its at-the-market offering program capacity to $60.0 million to enhance financial flexibility.

Intensity Therapeutics announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.

Intensity Therapeutics, Inc. furnished an updated financial highlights slide for the period ending December 31, 2025, noting the figures are unaudited and preliminary.

Intensity Therapeutics reports a net loss of $2.4 million for Q1 2026, with a significant decrease in R&D expenses due to paused clinical trial enrollments, while cash reserves remain a concern.

Intensity Therapeutics reported a reduced net loss for the nine months ended September 30, 2025, but paused two key clinical trials due to funding constraints and dosing regimen revisions, while raising additional capital to extend its cash runway.

Intensity Therapeutics reported reduced losses but paused its pivotal Phase 3 sarcoma trial due to funding constraints, raising substantial doubt about its ability to continue as a going concern.

Intensity Therapeutics reports a net loss of $3.3 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to limited cash reserves.

Intensity Therapeutics reported a net loss of $13.1 million for the nine months ended September 30, 2024, while progressing its clinical trials for cancer treatments.

Intensity Therapeutics' Q2 2024 report reveals a significant increase in research and development expenses, primarily driven by the initiation of a Phase 3 sarcoma study.

Intensity Therapeutics' latest 10-K details clinical advancements for its lead cancer drug INT230-6, alongside significant operating losses and ongoing funding needs.

Intensity Therapeutics files its 10-K, reporting on its financial performance for 2024 and outlining key clinical trial advancements.

Intensity Therapeutics' 10-K filing details clinical trial progress, manufacturing advancements, and future plans for their novel cancer treatment technology.

Thomas I H Dubin, a Director of Intensity Therapeutics, Inc., received 5,500 shares of common stock on July 16, 2026.

Daniel Donovan, a Director of Intensity Therapeutics, Inc., received 5,500 shares of common stock on July 16, 2026.

Mark A Goldberg, a Director of Intensity Therapeutics, Inc., received 5,500 shares of common stock on July 16, 2026.

Emer Leahy, a Director of Intensity Therapeutics, Inc., received 5,500 shares of common stock on July 16, 2026.

John M Wesolowski, Principal Accounting Officer of Intensity Therapeutics, Inc., received 11,000 shares of common stock on July 16, 2026.

Joseph Talamo, Chief Financial Officer of Intensity Therapeutics, Inc., received 34,000 shares of common stock on July 16, 2026.

Intensity Therapeutics, Inc. has issued its 2026 proxy statement detailing proposals for director elections, equity plan amendments, and auditor ratification.

Intensity Therapeutics, Inc. has filed definitive additional materials related to its proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Intensity Therapeutics, Inc. is seeking stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and improve marketability.

Intensity Therapeutics, Inc. has filed definitive additional materials with the U.S. Securities and Exchange Commission, supplementing its previously filed proxy statement.

Intensity Therapeutics, Inc. has announced its 2025 annual meeting of stockholders will be held virtually on July 17, 2025, to elect one director and ratify the appointment of EisnerAmper LLP as its independent registered public accounting firm.

Intensity Therapeutics has filed definitive additional materials related to its proxy statement with the SEC.

Intensity Therapeutics is planning a public offering of common stock and warrants to raise capital for clinical trials and general corporate purposes.

Intensity Therapeutics is launching a public offering to sell shares of common stock and warrants, aiming to raise capital for clinical trials and general corporate purposes.

Intensity Therapeutics is registering for resale 1,237,113 shares of common stock issuable upon the exercise of warrants previously acquired by a selling stockholder.

Armistice Capital and Steven Boyd report a 2.56% beneficial ownership stake in Intensity Therapeutics, Inc. common stock.

Sapient Capital LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 3.9% of Intensity Therapeutics, Inc.'s common stock as of June 30, 2025.

Armistice Capital, LLC and Steven Boyd have disclosed a 5.75% beneficial ownership stake in Intensity Therapeutics, Inc., holding 872,547 shares of common stock.

Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a passive beneficial ownership of 8.13% in Intensity Therapeutics, Inc. as of December 31, 2024.